The recessively inherited, adult onset, quadriceps sparing myopathy with a predilection for distal muscles has received multiple historic names. The disorder was described in 1981 in Japanese patients and termed Nonaka Distal Myopathy [1], later commonly referred to as Distal Myopathy with Rimmed Vacuoles (DMRV) (OMIM#605820). In 1984, the disorder was described as vacuolar myopathy sparing the quadriceps in Iranian-Jewish patients [2], later commonly referred to as Inclusion Body Myopathy 2 (IBM2) or Hereditary Inclusion Body Myopathy (HIBM) (OMIM#600737). Mapping of the causative gene to the same locus on chromosome 9 in different cohorts of patient [3, 4], and ultimately identification of mutations in the causative gene GNE in all cohorts [5, 6], confirmed that these myopathies are in fact the same condition. However, since identification of GNE as the common causative gene, the multiple historic names for the disorder continue to be used by research groups worldwide. This disease nomenclature becomes increasingly confusing for clinicians, patients and researchers. Therefore, an international consortium (of which the authors are also members) has recently proposed to rename the disorder “GNE myopathy”, substituting all previous disease definitions. We all are now using this new name and hope that it will become the only term worldwide. After initial discovery of GNE gene defects to be causative for GNE myopathy, eight different GNE mRNA splice variants were identified, encoding (at least theoretically) eight protein isoforms [7]. The human GNE gene (GenBank Gene ID: 10020, {"type":"entrez-nucleotide","attrs":{"text":"NC_000009","term_id":"568815589","term_text":"NC_000009"}}NC_000009; ENSEMBL ENSG00000159921) consists of 13 exons, but each of the individual GNE mRNA splice variants consists of fewer exons. However, for mutation annotation purposes, only two major transcripts are relevant, which together span all 13 exons (Figure 1) [7]. We provide NCBI GenBank accession numbers for the two major isoforms hGNE1 and hGNE2 in the text below, and provide their ENSEMBL IDs in Table 1. Figure 1 Human GNE mRNA transcripts and isoforms. Table 1 Most frequent GNE myopathy-associated GNE variants hGNE1 (GenBank {"type":"entrez-protein","attrs":{"text":"NP_005467","term_id":"4885285","term_text":"NP_005467"}}NP_005467) is the originally described GNE protein which covers 722 amino acids [5] and is, confusingly, encoded in GenBank by mRNA transcript variant 2 ({"type":"entrez-nucleotide","attrs":{"text":"NM_005476","term_id":"298566309","term_text":"NM_005476"}}NM_005476). The hGNE2 isoform ({"type":"entrez-protein","attrs":{"text":"NP_001121699","term_id":"190014632","term_text":"NP_001121699"}}NP_001121699) covers 753 amino acids and is encoded by the longest GNE mRNA transcript, variant 1 ({"type":"entrez-nucleotide","attrs":{"text":"NM_001128227","term_id":"298566310","term_text":"NM_001128227"}}NM_001128227). The discovery of the additional N-terminal sequence (and novel exon 1) [8] encoding hGNE2, is potentially confusing since most previous molecular and biochemical studies (including all mutation reports) refer to the hGNE1 isoform, while according to universally adapted gene/protein nomenclature rules the longest mRNA splice form ought to be used for annotating nucleotide/amino acid locations (http://www.hgvs.org/mutnomen/refseq.html). Hence, amino acid numbering of previously reported GNE studies (based on hGNE1 nomenclature), including patient mutation reports, should be supplemented with 31 amino acids to adhere to the current (hGNE2) nomenclature guidelines, and nucleotide numbering should be supplemented with 93 bases. For exon numbering, the numbering according to the entire 13 exon GNE gDNA gene ought to be used, which means that exon numbering of previously reported GNE studies (based on hGNE1 nomenclature) have to be supplemented with one exon. Adaptation to the hGNE2 nomenclature can initially be confusing; however, we strongly support adaptation of this ‘new’ nomenclature. Laboratories/researchers not familiar with the GNE myopathy field and disease/gene history will report patient mutations and research tools (antibodies, enzyme activities, siRNA, nextgen sequence databases, etc.) according to current universally adapted nomenclature rules. Moreover, although there are no variants reported yet in the additional 31 amino acids of hGNE2 (perhaps because this region has not been considered for mutation analysis in many patients), future variants in this region could not be accurately named using hGNE1 as a reference. To illustrate the new terminology, we list both hGNE2 (‘new’ nomenclature) and hGNE1 (previous nomenclature) classifications and up to date exon numbers of the most frequent GNE mutations associated with GNE myopathy in Table 1. However, since history will leave its tracks, we strongly suggest accompanying all future references to GNE with the appropriate GenBank accession numbers.